Abbott Laboratories (ABT) Net Cash Flow (2009 - 2026)

Abbott Laboratories has disclosed Net Cash Flow across 18 years of filings, most recently posting -$1.7 billion for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$1.7 billion, down 53.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $247.0 million (down 13.03% YoY), and the FY2025 annual result was $835.0 million, up 2.33% from the prior year.
• Net Cash Flow came in at -$1.7 billion for Q1 2026 at Abbott Laboratories, down from $1.0 billion in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $1.3 billion in Q2 2022 to a low of -$2.1 billion in Q1 2022.
• The 5-year median for Net Cash Flow is $162.0 million (2023), against an average of -$164.9 million.
• Across the five-year window, Net Cash Flow tumbled 269.71% in 2022 and jumped 612.77% in 2025, its largest moves.
• Abbott Laboratories' Net Cash Flow stood at $237.0 million in 2022, then slumped by 31.65% to $162.0 million in 2023, then fell by 12.96% to $141.0 million in 2024, then surged by 612.77% to $1.0 billion in 2025, then plunged by 268.76% to -$1.7 billion in 2026.
• The last three Net Cash Flow figures came in at -$1.7 billion (Q1 2026), $1.0 billion (Q4 2025), and $570.0 million (Q3 2025), per Business Quant data.